EFFECTS OF TNF-ALPHA ANTAGONISM IN PATIENTS WITH THE METABOLIC SYNDROME

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 该研究的目的是确定TNF-α阻断剂对代谢综合征患者的影响，如NCEP标准所定义。 先前的研究已经提出了一个潜在的“脂肪-血管”轴，从脂肪细胞衍生的细胞因子引发炎症，从而触发动脉粥样硬化的发展。 我们假设代谢综合征患者的TNF-α阻断会积极影响心脏风险的炎症标志物，如内皮功能和葡萄糖耐量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to determine the effect of TNF-alpha blockade in patients with Metabolic Syndrome, as defined by the NCEP criteria. Previous studies have suggested a potential "adipo-vascular" axis, the initiation of inflammation from adipocyte derived cytokins which trigger the development of atherosclerosis. We hypothesize TNF-alpha blockade in patients with metabolic syndrome will positively affect inflammatory markers of cardiac risk such as endothelial function and glucose tolerance.